The U.S. Food and Drug Administration didn’t find new safety concerns after reexamining Acadia Pharmaceutical’s drug to treat hallucinations and delusions caused by Parkinson’s disease.
San Diego-based Alliance Healthcare Foundation established has a new $2 million fund with the San Diego Foundation. That money will be split between the Multicultural Health Foundation and Somali Family Services.
Laura Shawver — perhaps best known as the CEO of Synthorx — launched the Clearity Foundation after her own experience with ovarian cancer.
United Therapeutics Corporation gained North American licensing rights to a lung disease drug from San Diego’s Samumed in a deal announced Sept. 17.
In 2000, the cost to sequence a genome stood at $100 million.
ViaCyte, a San Diego stem cell therapy biotech, has teamed up with a Massachusetts gene-editing company to take on diseases like diabetes.
San Diego-based Sherpa Clinical Packaging has been acquired by PCI Pharma Services under a deal announced Sept. 11 in which terms were not disclosed.
San Diego’s Vital Therapies on Sept. 12 scrapped a cell-based therapy intended to treat acute liver failure following final-stage clinical trials, sending the company’s stock plummeting.
Epic Sciences on Sept. 12 hauled in a $52 million Series E round to advance a portfolio of tests.
Vista-based Exagen Diagnostics launched a blood test for added insight in managing rheumatoid arthritis.
Halozyme Therapeutics hired pharmaceutical veteran Benjamin Hickey as the company’s chief commercial officer, it was recently announced.
A patent dispute between ResMed and Fisher & Paykel Healthcare has escalated.
A New York investment management firm has pledged $65 million to a new venture with UC San Diego to bridge the divide between basic research and clinical trials.
San Diego’s Gary and Mary West Foundation is helping get off the ground Civica RX, a new not-for-profit generic drug company with the goal of tackling shortages and high prices on life-saving medications.